Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of its Interleukin-31 Monoclonal Antibody for the Treatment of Atopic Dermatitis in Dogs

Stock Information for Kindred Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.